Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilobelimab - InflaRx

Drug Profile

Vilobelimab - InflaRx

Alternative Names: CaC-P29; Gohibic; IFX-1; Vilobelimab-InflaRx

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InflaRx
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pyoderma gangrenosum
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered COVID-19 pneumonia
  • Phase III Pyoderma gangrenosum
  • Phase II Hidradenitis suppurativa; Squamous cell cancer
  • Suspended Granulomatosis with polyangiitis; Microscopic polyangiitis
  • No development reported Inflammation
  • Discontinued Sepsis; Systemic inflammatory response syndrome

Most Recent Events

  • 11 Oct 2023 Updated efficacy and adverse events data from the phase II/III PANAMO trial in Pneumonia presented at the IDWeek 2023 (IDW-2023)
  • 31 Aug 2023 Preregistration for COVID-19 pneumonia in European Union (IV)
  • 15 Aug 2023 Phase-III clinical trials in Pyoderma gangrenosum in Australia (IV) (NCT05964413)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top